Douglas Hanahan

Summary

Country: Switzerland

Publications

  1. pmc Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes
    Olivier Nolan-Stevaux
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Genes Cancer 1:125-41. 2010
  2. ncbi request reprint Rethinking the war on cancer
    Douglas Hanahan
    Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences Swiss Federal Institute of Technology Lausanne EPFL, CH 1015 Lausanne, Switzerland Electronic address
    Lancet 383:558-63. 2014
  3. doi request reprint Hallmarks of cancer: the next generation
    Douglas Hanahan
    The Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences, EPFL, Lausanne CH 1015, Switzerland
    Cell 144:646-74. 2011
  4. ncbi request reprint A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
    Kristian Pietras
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California San Francisco, 513 Parnassas Avenue, San Francisco, CA 94143, USA
    J Clin Oncol 23:939-52. 2005
  5. pmc Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma
    Peter Olson
    Diabetes Center, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 108:E1275-84. 2011
  6. pmc Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms
    Danielle B Ulanet
    Diabetes Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e12454. 2010
  7. pmc Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis
    Hiroaki Nozawa
    Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 103:12493-8. 2006
  8. pmc MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
    Peter Olson
    Diabetes Center, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 23:2152-65. 2009
  9. doi request reprint Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner
    Neta Erez
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94143, USA
    Cancer Cell 17:135-47. 2010
  10. ncbi request reprint A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer
    Johanna A Joyce
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0534, USA
    Oncogene 24:4037-51. 2005

Collaborators

Detail Information

Publications47

  1. pmc Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes
    Olivier Nolan-Stevaux
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Genes Cancer 1:125-41. 2010
    ....
  2. ncbi request reprint Rethinking the war on cancer
    Douglas Hanahan
    Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences Swiss Federal Institute of Technology Lausanne EPFL, CH 1015 Lausanne, Switzerland Electronic address
    Lancet 383:558-63. 2014
    ..In this Series paper, I suggest that, much like in modern warfare, the war on cancer needs to have a battlespace vision...
  3. doi request reprint Hallmarks of cancer: the next generation
    Douglas Hanahan
    The Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences, EPFL, Lausanne CH 1015, Switzerland
    Cell 144:646-74. 2011
    ..Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer...
  4. ncbi request reprint A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
    Kristian Pietras
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California San Francisco, 513 Parnassas Avenue, San Francisco, CA 94143, USA
    J Clin Oncol 23:939-52. 2005
    ..Additionally, vascular endothelial growth factor receptor (VEGFR) inhibitors and metronomic chemotherapy show modest benefit against early- but not late-stage disease...
  5. pmc Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma
    Peter Olson
    Diabetes Center, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 108:E1275-84. 2011
    ..The demonstration of on-target activity but with discordant benefit in the PDAC and PNET GEMMs illustrates the potential value of linked preclinical and clinical trials...
  6. pmc Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms
    Danielle B Ulanet
    Diabetes Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e12454. 2010
    ..These findings demonstrate that Arf loss of function can promote tumorigenesis via facilitating angiogenesis, at least in part, through p53-independent mechanisms...
  7. pmc Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis
    Hiroaki Nozawa
    Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 103:12493-8. 2006
    ..Thus infiltrating neutrophils can play a crucial role in activating angiogenesis in a previously quiescent tissue vasculature during the early stages of carcinogenesis...
  8. pmc MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
    Peter Olson
    Diabetes Center, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 23:2152-65. 2009
    ..Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality...
  9. doi request reprint Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner
    Neta Erez
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94143, USA
    Cancer Cell 17:135-47. 2010
    ..Additionally, we show that normal dermal fibroblasts can be "educated" by carcinoma cells to express proinflammatory genes...
  10. ncbi request reprint A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer
    Johanna A Joyce
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0534, USA
    Oncogene 24:4037-51. 2005
    ..These data encourage clinical applications of inhibitors such as PI-88 for the many human cancers where heparanase expression is elevated or mobilization of HS-binding regulatory factors is implicated...
  11. pmc Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis
    Christopher W Chiu
    University of California, San Francisco, CA, USA
    J Clin Oncol 28:4425-33. 2010
    ..Toward that end, we investigated the potential benefit of dual therapeutic targeting of the epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) kinases, using a preclinical mouse model of PNET...
  12. pmc Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis
    Matthew G H Chun
    Department of Biochemistry and Biophysics, Helen Diller Family Comprehensive Cancer Center, and Diabetes Center, University of California San Francisco, San Francisco, California, USA
    PLoS Genet 6:e1001120. 2010
    ..Our results demonstrate that loss of desmoplakin expression and resultant disruption of desmosomal adhesion can promote increased local tumor invasion independent of adherens junction status...
  13. ncbi request reprint CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer
    Dylan Daniel
    Department of Biochemistry, Diabetes Center and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 0534, USA
    Cancer Res 65:2018-25. 2005
    ..Thus, an HPV16 E7 immunogen holds promise for noninvasive treatment and prevention of human cervical cancer...
  14. pmc Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
    Danielle B Ulanet
    Department of Biochemistry and Biophysics, Diabetes Center, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 107:10791-8. 2010
    ..The results predict that elevated IR signaling before and after treatment will respectively manifest intrinsic and adaptive resistance to anti-IGF-1R therapies...
  15. pmc Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer
    Jeffrey H Hager
    Diabetes and Hellen Diller Family Comprehensive Cancer Centers, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 4:e4455. 2009
    ....
  16. pmc Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B
    Beverly L Falcon
    Cardiovascular Research Institute, Comprehensive Cancer Center, Department of Anatomy, University of California, San Francisco, California, USA
    Am J Pathol 178:2920-30. 2011
    ..Together, these findings indicate that inhibition of PDGF-B signaling promotes the delivery and efficacy of chemotherapeutic agents by increasing the efficiency of tumor blood vessels...
  17. ncbi request reprint Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis
    Oriol Casanovas
    Department of Biochemistry and Biophysics, Diabetes Center and Comprehensive Cancer Center, University of California San Francisco, 94143, USA
    Oncogene 24:6597-604. 2005
    ....
  18. ncbi request reprint Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    Oriol Casanovas
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Cell 8:299-309. 2005
    ..These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition...
  19. pmc Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator
    Seiko Ishida
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
    Cancer Cell 17:574-83. 2010
    ..Our results identify the copper transporter as a therapeutic target, which can be manipulated with copper chelating drugs to selectively enhance the benefits of platinum-containing chemotherapeutic agents...
  20. ncbi request reprint Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis
    Johanna A Joyce
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Cancer Cell 4:393-403. 2003
    ..One peptide is homologous with pro-PDGF-B, which is expressed in endothelial cells, while its receptor is expressed in pericytes...
  21. ncbi request reprint Lymphatic zip codes in premalignant lesions and tumors
    Lianglin Zhang
    Cancer Research Center and Program in Molecular Pathology, Burnham Institute for Medical Research, La Jolla, California, USA
    Cancer Res 66:5696-706. 2006
    ....
  22. ncbi request reprint Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas
    Jeffrey H Hager
    Department of Biochemistry, University of California at San Francisco Diabetes and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer Res 64:2406-10. 2004
    ..These studies illustrate the utility of transgenic animal models for investigation of factors influencing genomic heterogeneity despite the commonalty of target cell type and initiating oncogene...
  23. pmc Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
    Eric A Collisson
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA
    Nat Med 17:500-3. 2011
    ..We further define gene signatures for these subtypes that may have utility in stratifying patients for treatment and present preclinical model systems that may be used to identify new subtype specific therapies...
  24. ncbi request reprint The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer
    Douglas Hanahan
    Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94143, USA
    Genes Dev 21:2258-70. 2007
    ....
  25. ncbi request reprint Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis
    Theresa Lopez
    Department of Biochemistry and Biophysics and the UCSF Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, 94143, USA
    Cancer Cell 1:339-53. 2002
    ..Notably, encapsulated tumors were absent; instead, invasive carcinomas with downregulated E-cadherin were prevalent, and the majority of mice had local lymph node metastasis...
  26. doi request reprint Accessories to the crime: functions of cells recruited to the tumor microenvironment
    Douglas Hanahan
    The Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne, CH 1015 Lausanne, Switzerland
    Cancer Cell 21:309-22. 2012
    ..This enhanced understanding presents interesting new targets for anticancer therapy...
  27. pmc An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis
    Enrico Giraudo
    Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA
    J Clin Invest 114:623-33. 2004
    ....
  28. pmc Modes of resistance to anti-angiogenic therapy
    Gabriele Bergers
    University of California, San Francisco, Department of Neurological Surgery, Brain Tumour Research Center, San Francisco, California 94143, USA
    Nat Rev Cancer 8:592-603. 2008
    ....
  29. pmc Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis
    Matthew G H Chun
    Department of Biochemistry and Biophysics, Diabetes Center, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 107:17268-73. 2010
    ..Collectively, our results demonstrate that tumor invasion is subject to polymorphic genetic control and identify Alk as a genetic modifier of invasive tumor growth...
  30. pmc Bioavailable copper modulates oxidative phosphorylation and growth of tumors
    Seiko Ishida
    Swiss Institute for Experimental Cancer Research and Laboratory for Integrative and Systems Physiology, Interfaculty Institute of Bioengineering, School of Life Sciences, and Biomedical Imaging Center, Institute of Physics of Biological Systems, Swiss Federal Institute of Technology Lausanne, CH 1015 Lausanne, Switzerland
    Proc Natl Acad Sci U S A 110:19507-12. 2013
    ..Thus, activation of glycolysis in tumors may in part reflect insufficient copper bioavailability in the tumor microenvironment. ..
  31. ncbi request reprint VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis
    Masahiro Inoue
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, CA 94143, USA
    Cancer Cell 1:193-202. 2002
    ..Thus, VEGF-A is crucial for angiogenesis in a prototypical model of carcinogenesis, whose loss is not readily compensated...
  32. pmc Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    Gabriele Bergers
    Department of Neurological Surgery, University of California, San Francisco Comprehensive Cancer Center, San Francisco, San Francisco, California 94115, USA
    J Clin Invest 111:1287-95. 2003
    ..Thus, combinatorial targeting of receptor tyrosine kinases shows promise for treating multiple stages in tumorigenesis, most notably the often-intractable late-stage solid tumor...
  33. pmc Endogenous Myc maintains the tumor microenvironment
    Nicole M Sodir
    Department of Pathology, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 25:907-16. 2011
    ....
  34. ncbi request reprint Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes
    David Argilla
    Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
    Cancer Cell 6:373-85. 2004
    ....
  35. ncbi request reprint Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring
    Donald M McDonald
    University of California at San Francisco, San Francisco, CA, USA
    J Immunother 27:161-75. 2004
    ..The third addressed the translation to the clinic and monitoring of antiangiogenic activity of agents in patients and novel trial designs. What follows is a summary of the discussions and findings of each session...
  36. pmc Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition
    Elizabeth Allen
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, The University of California at San Francisco, San Francisco, California, USA
    Clin Cancer Res 17:5299-310. 2011
    ....
  37. doi request reprint Retrospective: Judah Folkman (1933-2008)
    Douglas Hanahan
    Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA
    Science 319:1055. 2008
  38. doi request reprint A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy
    Michele De Palma
    The Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences, Swiss Federal Institute of Technology Lausanne EPFL, 1015 Lausanne, Switzerland
    Cancer Cell 24:559-61. 2013
    ....
  39. pmc Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response
    Jessica C Pahler
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Neoplasia 10:329-40. 2008
    ..If such tumor-promoting macrophages are suppressed, MMP-9(+) neutrophils are then recruited, providing alternative paracrine support for tumor angiogenesis and progression...
  40. ncbi request reprint Multiple roles for cysteine cathepsins in cancer
    Johanna A Joyce
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, California, USA
    Cell Cycle 3:1516-619. 2004
    ....
  41. pmc Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
    Ksenya Shchors
    Department of Pathology, Neurology, Neurological Surgery, and Pediatrics, Sandler Neurosciences Center, and Brain Tumor Research Center, University of California, San Francisco, CA 94158, USA
    Proc Natl Acad Sci U S A 110:E1480-9. 2013
    ....
  42. pmc Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer
    Zhu Alexander Cao
    Department of Biochemistry, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, CA 94143 0534, USA
    BMC Cancer 2:11. 2002
    ..Thus, an important goal for tumor immunotherapy is to identify ways to modulate in vivo anti-tumor immunity to achieve clinical efficacy. We investigate this proposition in a spontaneous mouse tumor model, Rip1-Tag2...
  43. pmc A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice
    Aurélien Godinat
    Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne, LCBIM, CH 1015 Lausanne, Switzerland
    ACS Chem Biol 8:987-99. 2013
    ..Lastly, the luciferin ligation reaction is 3 orders of magnitude faster than Staudinger ligation, suggesting further applications for both bioluminescence and specific molecular targeting in vivo...
  44. doi request reprint The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities
    Michele De Palma
    The Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences, Swiss Federal Institute of Technology Lausanne EPFL, CH 1015 Lausanne, Switzerland
    Mol Oncol 6:111-27. 2012
    ..By comprehensively interrogating both parenchyma and stroma of patients' cancers with a suite of parametric tools, the promise of mechanism-based therapy may truly be realized...
  45. pmc Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting
    Kristian Pietras
    Department of Biochemistry and Biophysics, Diabetes Center and Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States ofAmerica
    PLoS Med 5:e19. 2008
    ..We postulated that pharmacological targeting of putative stromal support functions, in particular those of cancer-associated fibroblasts, could have therapeutic utility, and sought to assess the possibility in a pre-clinical setting...
  46. pmc GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation
    Olivier Nolan-Stevaux
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 23:24-36. 2009
    ....
  47. ncbi request reprint Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors
    Douglas Hanahan
    University of California at San Francisco, San Francisco, California 94143, USA
    Cancer Res 63:3005-8. 2003
    ..The symposium was concluded with an overall discussion focused on basic questions related to the capability of immunity to exert tumor-favoring or antitumor effects depending on conditions determined by both tumor and host functions...